Chymase-containing mast cells in human arterial intima: Implications for atherosclerotic disease

被引:0
|
作者
Kovanen, PT [1 ]
机构
[1] Wihuri Res Inst, SF-00140 Helsinki, Finland
关键词
atherosclerosis; chymase; lipoproteins; mast cells; matrix metalloproteinases;
D O I
暂无
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Many of the mast cells present in human atherosclerotic lesions contain chymase. As the lesions progress to more severe forms, the number of such mast cells increases, and their activity (degree of degranulation) increases. Exocytosed heparin-bound chymase may be involved in the development of both early (fatty streaks) and late (thrombotic) atherosclerotic lesions. Experimental studies with rat serosal mast cells have revealed that chymase can degrade the apolipoprotein B-100 component of low-density lipoprotein (LDL) particles and the apolipoprotein A component of high-density lipoprotein (HDL) particles. Both of these chymase actions on apolipoproteins tend to increase the cholesterol content of macrophages and to convert them into the foam cells typical of early atherosclerotic lesions. In atheromatous plaques, the late atherosclerotic lesions, the chymase-containing mast cells may render the plaques unstable and their caps susceptible to rupture when chymase activates the interstitial procollagenase secreted by the macrophages in the plaque caps. Definition of the quantitative importance of chymase in the pathogenesis of atherosclerosis and its complications remains an exciting challenge for the future.
引用
收藏
页码:125 / 127
页数:3
相关论文
共 50 条
  • [1] DISTRIBUTION OF CHYMASE-CONTAINING MAST-CELLS IN HUMAN BRONCHI
    MATIN, R
    TAM, EK
    NADEL, JA
    CAUGHEY, GH
    JOURNAL OF HISTOCHEMISTRY & CYTOCHEMISTRY, 1992, 40 (06) : 781 - 786
  • [2] Quantitative analysis of tryptase- and chymase-containing mast cells in eosinophilic conditions of cats
    Noli, C
    Welle, M
    Scarampella, F
    Abramo, F
    VETERINARY PATHOLOGY, 2003, 40 (02) : 219 - 221
  • [3] QUANTITATION OF TRYPTASE-CONTAINING AND CHYMASE-CONTAINING MAST-CELLS IN CUTANEOUS LICHEN-PLANUS
    HARVIMA, IT
    NAUKKARINEN, A
    HARVIMA, RJ
    AALTO, ML
    NEITTAANMAKI, H
    HORSMANHEIMO, M
    ACTA DERMATO-VENEREOLOGICA, 1991, 71 (05) : 394 - 398
  • [4] Quantitative analysis of tryptase- and chymase-containing mast cells in atopic dermatitis and nummular eczema
    Jarvikallio, A
    Naukkarinen, A
    Harvima, IT
    Aalto, ML
    Horsmanheimo, M
    BRITISH JOURNAL OF DERMATOLOGY, 1997, 136 (06) : 871 - 877
  • [5] Chymase-Containing Mast Cells are Significantly Increased in Patients With Irritable Bowel Syndrome: A Role in Epithelial Permeability?
    Heuston, Sinead
    Quigley, Eamonn M.
    Hyland, Niall P.
    GASTROENTEROLOGY, 2012, 142 (05) : S827 - S827
  • [6] MAST-CELLS OF 2 TYPES DIFFERING IN NEUTRAL PROTEASE COMPOSITION IN THE HUMAN AORTIC INTIMA - DEMONSTRATION OF TRYPTASE-CONTAINING AND TRYPTASE/CHYMASE-CONTAINING MAST-CELLS IN NORMAL INTIMAS, FATTY STREAKS AND THE SHOULDER REGION OF ATHEROMAS
    KAARTINEN, M
    PENTTILA, A
    KOVANEN, PT
    ARTERIOSCLEROSIS AND THROMBOSIS, 1994, 14 (06): : 966 - 972
  • [7] QUANTITATIVE ENZYME-HISTOCHEMICAL ANALYSIS OF TRYPTASE-CONTAINING AND CHYMASE-CONTAINING MAST-CELLS IN PSORIATIC SKIN
    HARVIMA, IT
    NAUKKARINEN, A
    HARVIMA, RJ
    AALTO, ML
    NEITTAANMAKI, H
    HORSMANHEIMO, M
    ARCHIVES OF DERMATOLOGICAL RESEARCH, 1990, 282 (07) : 428 - 433
  • [8] An investigation of the therapeutic potential of chymase-containing mast cells in a preclinical model of irritable bowel syndrome and their translational relevance
    Hyland, N.
    Carroll, S.
    Heuston, S.
    Quigley, E.
    Cryan, J.
    NEUROGASTROENTEROLOGY AND MOTILITY, 2012, 24 : 63 - 63
  • [9] S-100 POSITIVE CELLS IN HUMAN ARTERIAL INTIMA AND IN ATHEROSCLEROTIC LESIONS
    BOBRYSHEV, YV
    LORD, RSA
    CARDIOVASCULAR RESEARCH, 1995, 29 (05) : 689 - 696
  • [10] Inhibitors of chymase as mast cell-stabilizing agents:: Contribution of chymase in the activation of human mast cells
    He, SH
    Gaça, MDA
    McEuen, AR
    Walls, AF
    JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, 1999, 291 (02): : 517 - 523